enGene (ENGN) Competitors

enGene (NASDAQ:ENGN) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends.

Which has more volatility and risk, ENGN or PRAX?

enGene has a beta of -0.4, indicating that its share price is 140% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500.

Does the MarketBeat Community favor ENGN or PRAX?

Praxis Precision Medicines received 34 more outperform votes than enGene when rated by MarketBeat users. However, 95.24% of users gave enGene an outperform vote while only 75.00% of users gave Praxis Precision Medicines an outperform vote.

Company	Underperform	Outperform
enGene	Outperform Votes 20 95.24%	Underperform Votes 1 4.76%
Praxis Precision Medicines	Outperform Votes 54 75.00%	Underperform Votes 18 25.00%

Do institutionals & insiders believe in ENGN or PRAX?

64.2% of enGene shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 10.4% of enGene shares are held by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is ENGN or PRAX more profitable?

enGene has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -9,409.22%. enGene's return on equity of -16.69% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-16.69%	-14.27%
Praxis Precision Medicines	-9,409.22%	-54.86%	-50.52%

Do analysts rate ENGN or PRAX?

enGene currently has a consensus target price of $23.29, indicating a potential upside of 602.43%. Praxis Precision Medicines has a consensus target price of $109.90, indicating a potential upside of 134.65%. Given enGene's stronger consensus rating and higher possible upside, equities analysts clearly believe enGene is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Praxis Precision Medicines	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Does the media favor ENGN or PRAX?

In the previous week, enGene had 12 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 16 mentions for enGene and 4 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.44 beat enGene's score of -0.10 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings & valuation, ENGN or PRAX?

enGene has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$55.14M	-$1.52	-2.18
Praxis Precision Medicines	$8.12M	117.46	-$123.28M	-$10.72	-4.37

Summary

enGene beats Praxis Precision Medicines on 11 of the 18 factors compared between the two stocks.